Literature DB >> 20050184

Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons.

Min Hu1, Murali Gopalakrishnan, Jinhe Li.   

Abstract

BACKGROUND AND
PURPOSE: alpha7-Nicotinic acetylcholine receptors (alpha7 nAChRs) play an important role in cognitive function. Positive allosteric modulators (PAMs) amplify effects of alpha7 nAChR agonist and could provide an approach for treatment of cognitive deficits in neuropsychiatric diseases. PAMs can either predominantly affect the apparent peak current response (type I) or increase both the apparent peak current response and duration of channel opening, due to prolonged desensitization (type II). The delay of receptor desensitization by type II PAMs raises the possibility of Ca2+-induced toxicity through prolonged activation of alpha7 nAChRs. The present study addresses whether type I and II PAMs exhibit different cytotoxicity profiles. EXPERIMENTAL APPROACH: The present studies evaluated cytotoxic effects of type I PAM [N-(4-chlorophenyl)]-alpha-[(4-chlorophenyl)-aminomethylene]-3-methyl-5-isoxazoleacet-amide (CCMI) and type II PAM 1-[5-chloro-2,4-dimethoxy-phenyl]-3-[5-methyl-isoxazol-3-yl]-urea (PNU-120596), or 4-[5-(4chloro-phenyl)-2-methyl-3-propionyl-pyrrol-1-yl]-benzenesulphonamide (A-867744). The studies used cultures of PC12 cells and primary cultures of rat cortical neuronal cells. KEY
RESULTS: Our results showed that neither type I nor type II PAMs had any detrimental effect on cell integrity or cell viability. In particular, type II PAMs did not affect neuron number and neurite outgrowth under conditions when alpha7 nAChR activity was measured by Ca2+ influx and extracellular signal-regulated kinases 1 and 2 phosphorylation, following exposure to alpha7 nAChR agonists. CONCLUSIONS AND IMPLICATIONS: This study demonstrated that both type I and type II alpha7 nAChR selective PAMs, although exhibiting differential electrophysiological profiles, did not exert cytotoxic effects in cells endogenously expressing alpha7 nAChRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20050184      PMCID: PMC2807647          DOI: 10.1111/j.1476-5381.2009.00474.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

Review 1.  Nicotinic acetylcholine receptors and the regulation of neuronal signalling.

Authors:  Federico Dajas-Bailador; Susan Wonnacott
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819

Review 2.  Nicotinic acetylcholine receptors as drug targets.

Authors:  R C Hogg; D Bertrand
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2004-04

3.  A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.

Authors:  Raymond S Hurst; Mihaly Hajós; Mario Raggenbass; Theron M Wall; Nicole R Higdon; Judy A Lawson; Karen L Rutherford-Root; Mitchell B Berkenpas; W E Hoffmann; David W Piotrowski; Vincent E Groppi; Geraldine Allaman; Roch Ogier; Sonia Bertrand; Daniel Bertrand; Stephen P Arneric
Journal:  J Neurosci       Date:  2005-04-27       Impact factor: 6.167

4.  Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells.

Authors:  Ke Ren; Viviana Puig; Roger L Papke; Yoshihito Itoh; Jeffrey A Hughes; Edwin M Meyer
Journal:  J Neurochem       Date:  2005-06-22       Impact factor: 5.372

5.  Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.

Authors:  Alice L Bodnar; Luz A Cortes-Burgos; Karen K Cook; Dac M Dinh; Vincent E Groppi; Mihaly Hajos; Nicole R Higdon; William E Hoffmann; Raymond S Hurst; Jason K Myers; Bruce N Rogers; Theron M Wall; Mark L Wolfe; Erik Wong
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

6.  SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.

Authors:  Philippe Pichat; Olivier E Bergis; Jean-Paul Terranova; Alexandre Urani; Christine Duarte; Vincent Santucci; Christiane Gueudet; Carole Voltz; Régis Steinberg; Jeanne Stemmelin; Florence Oury-Donat; Patrick Avenet; Guy Griebel; Bernard Scatton
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

7.  Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment.

Authors:  Peter Curzon; David J Anderson; Arthur L Nikkel; Gerard B Fox; Murali Gopalakrishnan; Michael W Decker; Robert S Bitner
Journal:  Neurosci Lett       Date:  2006-10-20       Impact factor: 3.046

8.  Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.

Authors:  Donn G Wishka; Daniel P Walker; Karen M Yates; Steven C Reitz; Shaojuan Jia; Jason K Myers; Kirk L Olson; E Jon Jacobsen; Mark L Wolfe; Vincent E Groppi; Alexander J Hanchar; Bruce A Thornburgh; Luz A Cortes-Burgos; Erik H F Wong; Brian A Staton; Thomas J Raub; Nicole R Higdon; Theron M Wall; Raymond S Hurst; Rodney R Walters; William E Hoffmann; Mihaly Hajos; Stanley Franklin; Galen Carey; Lisa H Gold; Karen K Cook; Steven B Sands; Sabrina X Zhao; John R Soglia; Amit S Kalgutkar; Stephen P Arneric; Bruce N Rogers
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

9.  Differential coupling of alpha7 and non-alpha7 nicotinic acetylcholine receptors to calcium-induced calcium release and voltage-operated calcium channels in PC12 cells.

Authors:  Jane A Dickinson; Katharine E Hanrott; M H Selina Mok; James N C Kew; Susan Wonnacott
Journal:  J Neurochem       Date:  2006-12-20       Impact factor: 5.372

10.  Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2.

Authors:  Silvia Miret; Els M De Groene; Werner Klaffke
Journal:  J Biomol Screen       Date:  2005-11-28
View more
  13 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Boosting Endogenous Resistance of Brain to Ischemia.

Authors:  Fen Sun; Stephen R Johnson; Kunlin Jin; Victor V Uteshev
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

3.  Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning.

Authors:  Morgane Milienne-Petiot; Kerin K Higa; Andrea Grim; Debbie Deben; Lucianne Groenink; Elizabeth W Twamley; Mark A Geyer; Jared W Young
Journal:  Eur Neuropsychopharmacol       Date:  2018-09-11       Impact factor: 4.600

4.  Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Mol Pharmacol       Date:  2011-09-01       Impact factor: 4.436

Review 5.  Nicotinic acetylcholine receptors at the single-channel level.

Authors:  Cecilia Bouzat; Steven M Sine
Journal:  Br J Pharmacol       Date:  2017-04-08       Impact factor: 8.739

6.  Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures.

Authors:  Dustin K Williams; Can Peng; Matthew R Kimbrell; Roger L Papke
Journal:  Mol Pharmacol       Date:  2012-07-24       Impact factor: 4.436

Review 7.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

Review 8.  α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum.

Authors:  Victor V Uteshev
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

9.  The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models.

Authors:  Kelen Freitas; F Ivy Carroll; M Imad Damaj
Journal:  J Pharmacol Exp Ther       Date:  2012-10-31       Impact factor: 4.030

Review 10.  The therapeutic promise of positive allosteric modulation of nicotinic receptors.

Authors:  Victor V Uteshev
Journal:  Eur J Pharmacol       Date:  2014-02-12       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.